文献速递肿瘤 PET/CT

非小细胞肺癌免疫检查点抑制剂治疗中的超进展:18F-FDG PET/CT的作用

Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT.
PubMed 文献 · J Nucl Med · 2019-12-20

该前瞻性研究纳入50例接受免疫检查点抑制剂治疗的非小细胞肺癌患者,基线行18F-FDG PET/CT及血液采样,发现14例出现超进展(HPD),HPD与高肿瘤代谢负荷(TLG、MTV)及多发转移、炎症指标相关,HPD组中位OS仅4个月。

要点

  • HPD组肿瘤代谢负荷更高:TLG 756.1 cm3 vs 475.6 cm3,MTV 287.3 vs 62.1。
  • HPD组85.7%有>2个转移部位,非HPD组仅25%。
  • HPD组中位OS 4个月,非HPD组15个月(P=0.003)。

核心结论

  • 基线高代谢肿瘤负荷和高炎症指标的患者接受ICIs可能出现HPD,需警惕。

研究设计与样本

  • 前瞻性收集50例接受ICIs治疗的非小细胞肺癌患者,基线行增强CT、18F-FDG PET/CT和外周血采样,中位随访12.4个月。

主要发现

  • 14例(28%)出现HPD,10例完全或部分缓解,17例疾病稳定,5例疾病进展。
  • HPD与TLG(756.1 cm3 vs 475.6 cm3,P=0.042)和MTV(287.3 vs 62.1,P=0.011)显著相关。
  • HPD组12/14例(85.7%)有>2个转移部位,非HPD组8/32例(25%),P<0.001。
  • 衍生中性粒细胞与淋巴细胞比值(dNLR)和血小板计数与HPD状态相关(P=0.038和P=0.025)。
  • HPD组中位OS 4个月,非HPD组15个月(P=0.003);多因素分析显示MTV和dNLR为OS独立预测因子。

临床怎么用

  • 基线18F-FDG PET/CT的MTV和TLG可辅助识别ICIs治疗前高HPD风险患者。
  • 结合dNLR、血小板计数和转移部位数量综合评估HPD风险。

局限性

  • 样本量较小(50例),仅46例可进行影像学疗效评估。
  • HPD定义基于临床和影像学标准,尚需更多研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A new pattern of response, so-called hyperprogressive disease (HPD), is emerging during treatment with immune checkpoint inhibitors (ICIs). Our aim was to investigate the prevalence of such a phenomenon and to assess its association with clinical variables and metabolic parameters by 18F-FDG PET/CT. Methods: Data from 50 patients (34 men and 16 women; median age, 73 y) with non-small cell lung carcinoma treated with ICIs were prospectively collected. All patients underwent contrast-enhanced CT, 18F-FDG PET/CT, and complete peripheral blood sampling at baseline before ICI treatment. HPD was defined according to clinical and radiologic criteria. Because of rapid disease progression or worsening of clinical condition, radiologic response assessment was available for only 46 of the 50 patients. Overall survival (OS) was analyzed using the Kaplan-Meier method and the log-rank test. A Cox proportional hazards regression analysis was used to evaluate factors independently associated with OS. Median follow-up was 12.4 mo (range, 9.7-15.2 mo). Results: We identified the following response categories: 10 cases as complete or partial response, 17 cases as stable disease, 5 cases as progressive disease, and 14 cases as HPD. Among metabolic parameters, we observed a statistically significant association between HPD status and tumor burden, expressed by both TLG (756.1 cm3 for HPD vs. 475.6 cm3 for non-HPD, P = 0.042) and MTV (287.3 for HPD vs. 62.1 for non-HPD, P = 0.011). Among clinical variables, 12 of 14 patients (85.7%) within the HPD group, compared with 8 of 32 patients (25%) in the non-HPD group, had more than 2 metastatic sites (P < 0.001). In addition, the derived neutrophil-to-lymphocyte ratio and platelet count were significantly associated with HPD status (P = 0.038 and P = 0.025, respectively). Survival analysis showed a median OS of 4 mo for the HPD group, compared with 15 mo for the non-HPD group (P = 0.003). Likewise, median OS was significantly different when we considered all the response categories: complete or partial response, stable disease, progressive disease, and HPD (P = 0.001). Finally, multivariate analysis identified metabolic tumor volume and derived neutrophil-to-lymphocyte ratio as independent predictors for OS. Conclusion: Our results suggest that the use of ICIs might represent a concern in patients with high metabolic tumor burden and inflammatory indices at baseline. However, additional studies are needed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Castello A, Rossi S, Mazziotti E, et al. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT. J Nucl Med. 2019. PMID: 31862803. doi:10.2967/jnumed.119.237768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。